The short answer: at the time of this update, cannabis remains a Schedule I controlled substance under federal law. The Drug Enforcement Administration (DEA) has proposed moving it to Schedule III, but that rule is not final. For CBD consumers, the practical impact so far is limited because hemp-derived CBD with less than 0.3% THC is already federally legal under the 2018 Farm Bill. The rescheduling debate matters most for cannabis products with higher THC, not for most CBD products on the market.
cannabis rescheduling latest updates
The rescheduling timeline: how we got here
The push to reschedule cannabis started with a review by the Department of Health and Human Services (HHS) in 2023. HHS recommended that cannabis be moved to Schedule III, citing evidence of medical use. The DEA then initiated its own review and published a proposed rule in May 2024. Public comments poured in, and the DEA scheduled an administrative hearing. That hearing began in late 2024 and continued into 2025. A DEA administrative law judge issued a recommendation, but the final decision rests with the DEA Administrator. As of this writing, no final rule has taken effect.
- August 2023: HHS recommends Schedule III.
- May 2024: DEA publishes proposed rescheduling rule.
- Late 2024 to 2025: Public comment period and administrative hearing.
- 2025 to 2026: DEA Administrator's final decision pending.
What Schedule III would change and what it would not
Moving cannabis to Schedule III would recognize it as a prescription drug with accepted medical use. It would not legalize recreational cannabis. It would also not automatically change FDA rules for CBD. Hemp-derived CBD is already legal under the Farm Bill. The main changes would affect research, banking, and taxation for the cannabis industry.
Potential benefits of rescheduling
- Easier clinical research on cannabis and cannabinoids.
- Tax deductions for licensed cannabis businesses under 280E.
- More banking access for state-legal operators.
Potential drawbacks and open questions
- FDA would still need to approve cannabis as a prescription drug.
- State-legal markets could face new federal oversight.
- CBD products might see stricter enforcement if THC analogs are included.
What this means for CBD consumers
If you buy CBD online, the rescheduling debate probably will not change your access to lab-tested, hemp-derived CBD. The key is to keep buying from brands that publish certificates of analysis. If rescheduling leads to tighter federal rules, third-party testing will become even more important. For now, the legal status of hemp CBD remains unchanged.
update on cannabis rescheduling
What to watch next
Watch for a final DEA rule or a formal withdrawal of the proposal. Also watch Congress, which could pass standalone cannabis legislation. Until then, the regulatory landscape for CBD stays the same: hemp-derived CBD is legal federally, but state laws vary. Always check your state's rules.